people reached through BMS'
health equity grants (2020-2024)
2024 Impact Report - Bristol Myers Squibb
“
BMS has made significant strides in environmental sustainability and social impact. Coupled with our ongoing emphasis on transparency and ethical governance, we aim to provide long-term value creation and positive impact for our patients, our people and the planet. 
Christopher S. Boerner, Ph.D.
”
ENVIRONMENTAL, SOCIAL AND GOVERNANCE
Our annual impact report describes our commitment to building a better future and provides our performance across environmental sustainability, social impact and ethical governance.
Recent sustainability & social impact highlights
Low- and middle-income countries
(LMICs) have potential direct import
(DI) access for 14 BMS medicines
new product fillings in
low-and middle-income countries (LMICs)
patients reached globally*
assets in early-stage
clinical development
BMS received
SBTi target approval
* Excluding established brands (Baraclude, Abraxane, Vidaza, Reyataz and Nulojix)